Boerries Brandenburg
Overview
Explore the profile of Boerries Brandenburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1762
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swart M, Allen J, Reed B, Izquierdo Gil A, Verspuij J, Schmit-Tillemans S, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772095
Background: No vaccine for the prevention of HMPV is currently licensed, although several subunit vaccines are in development. Saponin-based adjuvant systems (AS), including QS-21, have transformed the field of subunit...
2.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
3.
Tang C, Verwilligen A, Sadoff J, Brandenburg B, Sneekes-Vriese E, van den Kerkhof T, et al.
NPJ Vaccines
. 2024 Jan;
9(1):8.
PMID: 38184641
The quantitation of antibody responses is a critical requirement for the successful development of vaccines and therapeutics that often relies on the use of standardized reference materials to determine relative...
4.
Swart M, Kuipers H, Milder F, Jongeneelen M, Ritschel T, Tolboom J, et al.
NPJ Vaccines
. 2023 Nov;
8(1):176.
PMID: 37952003
Seasonal influenza vaccines must be updated annually and suboptimally protect against strains mismatched to the selected vaccine strains. We previously developed a subunit vaccine antigen consisting of a stabilized trimeric...
5.
Sadoff J, Le Gars M, Brandenburg B, Cardenas V, Shukarev G, Vaissiere N, et al.
Vaccine
. 2022 Jun;
40(32):4403-4411.
PMID: 35667914
Background: Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting. Methods: In randomized, double-blind, placebo-controlled,...
6.
Milder F, Jongeneelen M, Ritschel T, Bouchier P, Bisschop I, de Man M, et al.
Proc Natl Acad Sci U S A
. 2022 Feb;
119(6).
PMID: 35131851
For an efficacious vaccine immunogen, influenza hemagglutinin (HA) needs to maintain a stable quaternary structure, which is contrary to the inherently dynamic and metastable nature of class I fusion proteins....
7.
Solforosi L, Kuipers H, Jongeneelen M, Huber S, van der Lubbe J, Dekking L, et al.
J Exp Med
. 2021 Apr;
218(7).
PMID: 33909009
Safe and effective coronavirus disease-19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and...
8.
Carreno J, McDonald J, Hurst T, Rigsby P, Atkinson E, Charles L, et al.
Vaccines (Basel)
. 2020 Nov;
8(4).
PMID: 33182279
The stalk domain of the hemagglutinin has been identified as a target for induction of protective antibody responses due to its high degree of conservation among numerous influenza subtypes and...
9.
van Dongen M, Kadam R, Juraszek J, Lawson E, Brandenburg B, Schmitz F, et al.
Science
. 2019 Mar;
363(6431).
PMID: 30846569
Recent characterization of broadly neutralizing antibodies (bnAbs) against influenza virus identified the conserved hemagglutinin (HA) stem as a target for development of universal vaccines and therapeutics. Although several stem bnAbs...
10.
Laursen N, Friesen R, Zhu X, Jongeneelen M, Blokland S, Vermond J, et al.
Science
. 2018 Nov;
362(6414):598-602.
PMID: 30385580
Broadly neutralizing antibodies against highly variable pathogens have stimulated the design of vaccines and therapeutics. We report the use of diverse camelid single-domain antibodies to influenza virus hemagglutinin to generate...